PROP 38: The Immunology and Immunotherapy Research Bond

• Who proposed it? Filed and bankrolled by Dr. Gary K. Michelson, a retired surgeon and philanthropist, through Olson Remcho, LLP. Administration would run through the California Department of Public Health, which selects the UC-affiliated institute [1, Sec. 130351(c),(e)]. An Advisory and Accountability Research Council, made up of the seven UC campus chancellors with medical or research programs plus ten to fifteen additional members, would oversee grant selection [1, Sec. 130355]. A Citizens’ Financial Accountability Oversight Committee would handle fiscal oversight [1, Sec. 130351(a)].
• What would it accomplish? A total of $8.4 billion in general obligation bonds, split evenly between one UC-affiliated nonprofit institute and a statewide grant program, with over $4 billion reserved for cancer, heart disease, and Alzheimer’s research.
• Where would it take effect? Statewide. Grants are limited to California-based public and nonprofit institutions, and licensed products must be sold to California patients at a 20 percent discount [1, Sec. 3(b),(i)].
• When is it decided? On the November 3, 2026, ballot. Bonds would be issued over time as the program spends the money, with repayment stretching across roughly twenty-five years.
• Why are supporters promoting it and why do opponents oppose it? The proponent argues immunology and immunotherapy are on the brink of transformative breakthroughs against cancer and other chronic diseases, and that a dedicated, reliable funding stream would keep California at the front of that science [1, Sec. 2]. Opponents question whether the state should borrow at this scale for research that federal agencies, universities, and private capital already fund.

The core trade-off is cost against uncertain return. The $8.4 billion is borrowed money. The Legislative Analyst estimates repayment of about $500 million a year for roughly twenty-five years, which comes to roughly $12.5 billion in total payments and, in the Legislative Analyst’s inflation-adjusted terms, about 10 percent more than the amount borrowed. That money is paid out of the general fund, the same account that funds schools, healthcare, and public safety. The measure’s headline promise that this is “effectively a loan program” rests on the 10 percent revenue-return provision, but the LAO is blunt that any such revenue is uncertain and could take decades to materialize, if it arrives at all.

The stem-cell precedent is the guide here because Proposition 38 copies its structure. California has poured billions into the California Institute for Regenerative Medicine since 2004. By most accounts, the science produced real value in training, facilities, and early-stage discovery. But the direct financial return to the state has been minimal. Under Proposition 71’s revenue-sharing rule, the state had received on the order of only a few hundred thousand dollars from funded inventions by the early 2020s, against $3 billion borrowed. The stem-cell agency also drew years of litigation and criticism over governance and conflicts of interest, given a board dominated by the same institutions eligible for its grants. Proposition 38 places the seven UC chancellors at the center of the council that steers the money, which invites the same question about whether the grant-makers and the grant-seekers are too close.

The argument on the other side is that basic biomedical research is a classic public good that private markets underfund because the payoff is distant, uncertain, and hard to capture. The measure’s supporters can point to the fact that the overwhelming majority of drugs approved by the FDA trace back to publicly funded research [1, Sec. 2(g)]. If even one major therapy for cancer or Alzheimer’s emerges, the human and fiscal value could dwarf the bond cost. The 20 percent California price discount and the 2 percent administrative cap are genuine attempts to answer the criticisms that dogged the stem-cell program. Whether those provisions work in practice, and whether the state should take on this much debt to find out, is what voters are deciding.

In addition, California voters have approved numerous general obligation bonds totaling over $50 billion in the last decade alone. One other measure on the ballot this year, Proposition 1, would authorize an $11.25 billion general obligation bond. The state is repaying about $80 billion in general obligation bonds right now. Local borrowing runs larger still. School and community college districts alone won voter approval for $138 billion in general obligation authority over the same period, repaid through property taxes rather than the general fund.

California has run this experiment before with stem-cell research. It borrowed billions, funded real science, and got back only a trickle of direct revenue. Before you vote, ask whether Proposition 38’s accountability provisions are strong enough to produce a different result, or whether you are being asked to repeat the same bet at nearly twice the size.

This is $8.4 billion in borrowed money repaid from the same fund that pays for schools and healthcare. Do you believe the state should take on that debt to accelerate research the market underfunds, or that this is a role for the federal government, universities, and private capital rather than California’s general fund?